A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- 09 Sep 2009 Actual end date (Dec 2006 ) added as reported by ClinicalTrials.gov.
- 05 Sep 2005 New trial record.